SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Apomorphine Products

Drug Requested: (Select drug below)

❑ **Apokyn®** (apomorphine hydrochloride) **subcutaneous injection**	❑ **apomorphine hydrochloride subcutaneous injection**
❑ **Onapgo™** (apomorphine hydrochloride) **subcutaneous continuous infusion**	

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Recommended Dosage:

- **Apokyn or apomorphine hydrochloride:** Initial dose is 0.2 mL (2 mg) gradually titrated and required under medical supervision; Maximum recommended dose is 0.6 mL (6mg). Quantity Limit: 6 boxes (90mL) per month.

(Continued on next page)

- **Onapgo:** Initial continuous dosage is 1 mg/hr with a maximum of 6 mg/hr for up to 16 hours per day. An extra dose may be titrated in increments of 0.5 mg or 1 mg based on clinical response and tolerability. Subsequent extra doses are between 0.5 mg and 2 mg, with at least 3 hours between extra doses and a maximum of 3 extra doses per day. Maximum recommended total daily dosage of Onapgo, including the continuous dosage and any extra dose(s), is 98 mg (1 cartridge per day) generally administered over the waking day (e.g., 16 hours). Quantity Limit: 6 cartons (30 cartridges; 600 mL) per 30 days.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 12 months

- ❑ Member must be 18 years of age or older
- ❑ Medication must be prescribed by, or in consultation with a neurologist
- ❑ Member is receiving concurrent therapy with carbidopa/levodopa **within the past 30 days AND** requested medication will be used in combination with continuous carbidopa/levodopa treatment **(verified by chart notes and/or pharmacy paid claims)**
- ❑ Provider has made adjustments to members carbidopa/levodopa dose in order to manage symptoms without success
- ❑ Member is **NOT** currently taking a 5-HT3 antagonist medication such as Zofran® (ondansetron), Kytril® (granisetron), Aloxi® (palonostron), Lotronex® (alosetron), or Anzemet® (dolasetron) which can result in profound hypotension and loss of consciousness **(verified by chart notes and/or pharmacy paid claims)**
- ❑ Member has received a starting dose of requested medication and did **NOT** develop clinically significant orthostatic hypotension
- ❑ Member does **NOT** have hypersensitivity to apomorphine, its excipients or sodium metabisulfite
- ❑ Member must meet all applicable medication specific criteria below

For Apokyn® and apomorphine hydrochloride requests: All clinical criteria MUST be met

- ❑ Member must have a confirmed diagnosis of Parkinson's disease in an individual who is having intermittent "OFF" episodes while on continuous carbidopa/levodopa therapy
- ❑ Member has had previous inadequate responses to or has been intolerant of at least **TWO** different classes of medications for the treatment of Parkinson's disease (e.g., monoamine oxidase type B inhibitor, dopamine agonist, or COMT inhibitor) **(verified by chart notes and/or pharmacy paid claims)**

(Continued on next page)

- ❑ Member has had an unsuccessful 30-day trial of *Inbrija™ **AND** *Nourianz™ **(*both prerequisite drug therapies require prior authorization – see www.sentarahealthplans.com for prior authorization form; chart notes must be submitted to document medication failures)**

For Onapgo™ (apomorphine subcutaneous infusion) requests: All clinical criteria MUST be met

- ❑ Member has a diagnosis of advanced Parkinson's disease (PD) with complicated motor fluctuations
- ❑ Member does **NOT** have a diagnosis of atypical PD or secondary PD
- ❑ Member is experiencing "OFF" episodes such as muscle stiffness, slow movements, or difficulty starting movements
- ❑ Provider has submitted documentation which confirms members' symptoms have **NOT** been adequately controlled with optimal medical therapy using **ALL** the following agents:
  - ❑ Dopamine agonist (e.g., Apokyn® or apomorphine hydrochloride, Neupro®, pramipexole, ropinirole)
  - ❑ **ONE** agent from any of the following classes:
    - ❑ Catechol-0-methyl transferase (COMT) inhibitor (e.g., entacapone, Ongentys®, tolcapone)
    - ❑ Monoamine oxidase B (MAO-B) inhibitor (e.g., rasagiline, selegiline, Xadago®)
    - ❑ Adenosine receptor antagonist (e.g., Nourianz®)

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Provider must submit chart notes confirming a positive clinical response to therapy, such as continued success in reversing "OFF" episodes, improved motor function, or clinically significant improvement or stabilization in the signs and symptoms of the disease
- ❑ Member continues to meet all initial criteria and has an absence of drug toxicity

Medication being provided by Specialty Pharmacy – Proprium Rx

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*

***Approved by Pharmacy and Therapeutics Committee**: ~~11/21/2019; 10/16/2020; 5/22/2025;~~ **11/20/2025**
REVISED/UPDATED/REFORMATTED: ~~2/3/2020; 11/2/2020; 10/11/2021. 6/09/2025,~~ **12/12/2025**